OPEN Health

Overview

OPEN Health is an integrated market access, HEOR, real-world evidence, and medical communications partner for pharma and biotech launch teams. Its strongest public buyer read is not a narrow medical-affairs-outsourcing motion; it is the ability to connect evidence generation, reimbursement strategy, value communication, KOL engagement, publications, and scientific commercialization under one program.

For a biopharma launch team, OPEN Health belongs on the shortlist when payer evidence, HTA readiness, real-world evidence, medical narrative, and scientific communications need to stay coordinated. It is especially relevant for oncology, rare disease, cell and gene therapy, and specialty launches where access strategy and clinical value story cannot be separated from publications, KOL engagement, and medical education.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, OPEN Health is evaluated as integrated market access, HEOR, real-world evidence, and medical communications partner for pharma and biotech launch teams.

Capability	Buyer should compare	OPEN Health readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core access strategy. OPEN Health combines market access consulting with HEOR, RWE, and scientific communications, making it useful where access strategy depends on evidence and medical narrative.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Strategy-led; validate execution depth. Treat OPEN Health as stronger for pricing / reimbursement strategy and value communication than for contracting execution or GTN operations unless the proposed team shows relevant launch analogs.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Core evidence work. Pharmerit heritage gives the platform a credible HEOR and evidence-planning base, with RWE and evidence-generation support connected to payer and HTA needs.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Documented / integrated. The best fit is payer and stakeholder engagement tied to value story, scientific communications, publications, and KOL strategy; validate payer-panel depth by geography.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Confirm policy strategy in the RFP. OPEN Health has strong HTA, reimbursement, and evidence-generation fit; buyers should validate U.S. policy, Medicaid, 340B, and channel-operations depth when those are central.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Strong integrated-planning fit. OPEN Health is best used when evidence, access, medical communications, KOL engagement, and publication planning need one operating plan; validate handoffs to hub, field reimbursement, and account teams.

Buyer Fit

• Shortlist when: Use OPEN Health when access, evidence, and medical narrative are intertwined enough that a standalone pricing boutique or standalone medcomms agency would create coordination risk.
• Therapy and product fit: Current metadata points to Oncology, Neurology, Rare Disease, Immunology/Autoimmune, Cardiology, Endocrinology/Diabetes, Ophthalmology, Infectious Disease, Gastroenterology, Dermatology; drug-type fit is Small Molecule, Biologics, Gene Therapy, Cell Therapy, Biosimilars, Specialty.
• Commercial fit: Pricing is custom/RFP, so define senior-team commitment, evidence deliverables, data rights, medical-review workflow, launch timing, and handoff responsibilities in the statement of work.
• Best-fit buyers: Pharma manufacturers and biotechs preparing specialty or global launches where payer evidence, RWE, value story, publications, and KOL engagement need one plan.
• Commercial diligence: Confirm which payer inputs are primary research, which evidence deliverables are reusable by account / medical teams, and where OPEN Health stops versus hub, field reimbursement, specialty pharmacy, or contracting operators.

Differentiators

• Evidence-to-communications model: OPEN Health can move from HEOR and evidence planning into value communication, scientific narrative, publications, and stakeholder engagement without forcing buyers to coordinate separate vendors.
• Pharmerit HEOR heritage: The inherited health-economics bench is a real differentiator when the launch needs cost-effectiveness, evidence synthesis, RWE, and payer / HTA communication depth.
• Medical communications scale: Full-spectrum medical and scientific communications keep publication planning, congress activity, KOL engagement, and payer-facing value narrative aligned.
• AI-enabled evidence work: The fusion partnership and related AI emphasis support KOL mapping, evidence extraction, and literature-review acceleration; buyers should diligence governance, review, and client-data controls.
• Global operating footprint: The company is a better fit for multi-market launches than small single-market projects because its value comes from coordinating global access, evidence, and communications work.

RFP Questions

• Which payer, HTA, clinician, and patient inputs are primary research versus secondary analysis or consultant judgment?
• How will HEOR, RWE, publications, KOL engagement, and payer value story be governed as one launch workstream?
• Which deliverables can be used directly by account teams, medical affairs, field reimbursement, and downstream patient-services partners?
• What AI-enabled evidence or literature-review tools will touch client data, and what medical, legal, regulatory, and audit controls apply?
• Which responsibilities does OPEN Health stop: strategy, evidence, message testing, publications, field tools, hub handoff, or ongoing access operations?

Recent Activity

• February 2026: Major strategic leadership appointments added enterprise growth, brand and communications, client-partner, and promotional medical education leaders.
• September 2025: Net-zero targets validated by Science Based Targets initiative (SBTi), including a Scope 3 emissions-reduction commitment.
• August 2025: Zack Lentz appointed Chief Commercial Officer to accelerate enterprise growth and integrated patient-centered commercialization.
• March 2025: Matt D’Auria appointed CEO to drive innovation and growth across the integrated platform.
• June 2024: Announced exclusive fusion AI partnership for AI-powered KOL mapping, evidence generation automation, and HEOR data extraction.
• 2025-2026: Public evidence-generation and AI-in-literature-review activity reinforces OPEN Health’s positioning around reimbursement, RWE, and evidence synthesis rather than a pure agency or field-medical model.